Heat shock proteins (HSPs) based anti-cancer vaccines
/in Hyperthermia, International Publications /von 2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-97[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
/in Breast Cancer, Hyperthermia, International Publications /von 2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-9Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
/in Colorectal Cancer, Hyperthermia, International Publications /von 2012-09-24 / Int J Hyperthermia 2012;28(8):707-14Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
/in Colorectal Cancer, Hyperthermia, International Publications /von 2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-61Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2012-07-27 / Int J Hyperthermia 2012;28(7):597-604Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
/in Hyperthermia, International Publications, NSCLC /von 2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22Old and new facts about hyperthermia-induced modulations of the immune system
/in Hyperthermia, International Publications /von 2012-06-12 / Int J Hyperthermia 2012;28(6):528-42Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
/in Cervical Cancer, Hyperthermia, International Publications /von 2012-06-12 / Int J Hyperthermia 2012;28(6):554-61
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de